Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Dependence on User Fees Would Increase Under FY 2012 Budget Request

This article was originally published in The Pink Sheet Daily

Executive Summary

Three new fees, including generic drug user fee, would help boost collections to $1.62 billion.

You may also be interested in...



FDA Budget May Need To Be Trimmed 5% In FY 2015

OMB memo states that agencies should reduce net discretionary spending from the initial FY 2015 estimate and provide options for additional cuts.

User Fee Triggers Require Care In Unfriendly Budget Environment, Ventimiglia Says

Trigger changes could feed argument that user fees are a tax on industry.

FDA's Medical Countermeasure Program Among Senate Funding Priorities

FDA should spend $19 million of an increase in non-user fee funding in fiscal 2012 on the agency’s medical countermeasures effort, the Senate Appropriations Committee recommends in the report that accompanies the Agriculture/FDA appropriations bill approved by the panel Sept 8.

Related Content

Topics

UsernamePublicRestriction

Register

PS071823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel